Publications by authors named "Jesus A Valero"
Imaging studies have transformed the diagnosis of large vessel vasculitis (LVV) involvement in giant cell arteritis (GCA). A positron emission tomography/computed tomography (PET/CT) scan with 18-fluorodeoxyglucose (18F-FDG) has emerged as a valuable tool for assessing LVV. We aimed to determine the utility of an 18F-FDG-PET/CT scan in detecting LVV in GCA in the ARTESER registry.
View Article and Find Full Text PDFArticle Synopsis
- - The study aimed to analyze how common visual symptoms are in patients with Giant Cell Arteritis (GCA) and what factors might predict these symptoms.
- - Out of 1,636 patients with GCA, 36.6% experienced visual issues, with anterior ischemic optic neuropathy being the most common complication; older age and jaw claudication were identified as risk factors for visual involvement.
- - Conversely, conditions like polymyalgia rheumatica, fever, longer symptom duration, and higher erythrocyte sedimentation rate were associated with a lower risk of experiencing visual symptoms.
Correction to: Real-world Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis patients in Spain: Results of a multicenter, observational study in routine clinical practice (The ORBIT-RA Study).
Rheumatol Ther
August 2022
Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study).
Rheumatol Ther
April 2022
Introduction: Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved to treat rheumatoid arthritis (RA). This study aimed to investigate patients' characteristics, prescription patterns, effectiveness, and treatment persistence in patients receiving baricitinib in real-world practice in Spain.
Methods: This retrospective longitudinal cohort study conducted in five rheumatology units included adults with RA initiating baricitinib (Sep-2017-May-19) with at least a 6-month-follow-up.